HTBX Heat Biologics, Inc.

0.59
-0.0002  -0%
Previous Close 0.59
Open 0.59
Price To book 1.67
Market Cap 21.01M
Shares 35,619,000
Volume 232,586
Short Ratio 14.89
Av. Daily Volume 478,256

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 ongoing data released March 21, 2017.
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 2 trial did not meet primary endpoint - November 30, 2016.
HS-410
Bladder cancer
Phase 1b data released December 6, 2016.
HS-110
Non-small cell lung cancer (NSCLC)